Clearside Biomedical provides NDA update for XIPEREᵀᴹ
Clearside Biomedical announced an update regarding the Company’s 505(b)(2) New Drug Application for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) with the FDA. The Company plans to re-submit the NDA in the first quarter of 2020 with the requested stability data. August 22, 2019